Vaxcyte’s VAX-31 Shows Promise in Pneumococcal Disease Trial
Company Announcements

Vaxcyte’s VAX-31 Shows Promise in Pneumococcal Disease Trial

An update from Vaxcyte (PCVX) is now available.

Vaxcyte, Inc. revealed promising initial results from its study on VAX-31, a vaccine candidate for preventing invasive pneumococcal disease in adults over 50. The Phase 1/2 trial showed that the vaccine was safe, well-tolerated, and effective in generating an immune response, indicating potential for future use in combating this serious infection.

Learn more about PCVX stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskVaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical Challenges
TipRanks Auto-Generated NewsdeskVaxcyte Reports Progress and Strengthens Financial Position
TheFlyVaxcyte reports Q3 EPS (83c), consensus ($1.13)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App